Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) overview
Extranodal marginal zone B-cell lymphoma (EMZL), also known as mucosa-associated lymphoid tissue (MALT) lymphoma, is a rare type of non-Hodgkin lymphoma that originates in the marginal zone B cells outside of the lymph nodes. It often develops in various extranodal sites of the body, particularly mucosal tissues such as the stomach, salivary glands, lungs, thyroid, and other organs. MALT lymphoma represents a small percentage of non-Hodgkin lymphomas. It is most diagnosed in adults, with a median age at diagnosis typically in the 60s, although it can occur at any age. MALT lymphoma often arises due to chronic inflammation or immune responses in specific tissues, leading to the proliferation of marginal zone B cells. In many cases, it is associated with chronic infections or autoimmune disorders that trigger persistent antigen stimulation, such as Helicobacter pylori infection in gastric MALT lymphoma or Sjögren’s syndrome in salivary gland MALT lymphoma.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
